Brainsway Ltd (BWAY)vsEli Lilly and Company (LLY)
BWAY
Brainsway Ltd
$9.39
-7.12%
HEALTHCARE · Cap: $406.96M
LLY
Eli Lilly and Company
$1,433.55
-0.82%
HEALTHCARE · Cap: $1.27T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 142353% more annual revenue ($86.46B vs $60.70M). LLY leads profitability with a 31.9% profit margin vs 15.6%. BWAY trades at a lower P/E of 42.1x. LLY earns a higher WallStSmart Score of 74/100 (B).
BWAY
Buy51
out of 100
Grade: C-
LLY
Strong Buy74
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.4% year-over-year
Earnings expanding 59.8% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 51.2%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Distress zone — elevated risk
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BWAY
The strongest argument for BWAY centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 15.6% and operating margin at 12.5%. Revenue growth of 35.4% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : BWAY
The primary concerns for BWAY are Market Cap, P/E Ratio, Altman Z-Score. A P/E of 42.1x leaves little room for execution misses.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.
Key Dynamics to Monitor
LLY carries more volatility with a beta of 0.39 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (74/100 vs 51/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Brainsway Ltd
HEALTHCARE · MEDICAL DEVICES · USA
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?